What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
作者信息
Jiang Yixing, Owonikoko Taofeek K, Ramalingam Suresh S, Khuri Fadlo R, Belani Chandra P
机构信息
Penn State Hershey Cancer Institute, Hershey, PA, USA.
出版信息
Ther Adv Med Oncol. 2010 Jul;2(4):229-35. doi: 10.1177/1758834010368045.
Abstract
摘要
相似文献
1
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?维持治疗在非小细胞肺癌治疗中的作用是什么？
Ther Adv Med Oncol. 2010 Jul;2(4):229-35. doi: 10.1177/1758834010368045.
2
Maintenance therapy in non-small cell lung cancer.非小细胞肺癌的维持治疗
Expert Rev Anticancer Ther. 2015;15(7):839-46. doi: 10.1586/14737140.2015.1052410. Epub 2015 May 31.
3
Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.树突状细胞维持治疗对晚期非小细胞肺癌患者细胞因子诱导的杀伤细胞的影响。
Tumori. 2012 May-Jun;98(3):314-9. doi: 10.1177/030089161209800306.
4
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.估计肌酐清除率与培美曲塞作为晚期非鳞状非小细胞肺癌延续维持治疗的疗效和毒性相关。
Clin Lung Cancer. 2015 Nov;16(6):e131-40. doi: 10.1016/j.cllc.2015.01.001. Epub 2015 Jan 10.
5
Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.拉库替尼单抗在非小细胞肺癌中的维持和二线治疗。
MEDICC Rev. 2021 Jul-Oct;23(3-4):21-28. doi: 10.37757/MR2021.V23.N3.5. Epub 2021 Aug 22.
6
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA.美国非小细胞肺癌患者采用帕博利珠单抗联合培美曲塞和铂类药物进行真实世界维持治疗的生存结局。
Immunotherapy. 2023 Mar;15(4):267-281. doi: 10.2217/imt-2022-0166. Epub 2023 Feb 15.
7
The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.维持治疗在老年非小细胞肺癌患者治疗中的作用：一项随机对照试验的荟萃分析
Drug Des Devel Ther. 2017 Dec 1;11:3435-3440. doi: 10.2147/DDDT.S145025. eCollection 2017.
8
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.培美曲塞联合贝伐珠单抗或紫杉醇联合贝伐珠单抗一线治疗晚期非鳞非小细胞肺癌的临床选择及最佳维持治疗：一项荟萃分析随机对照试验的证据。
BMC Cancer. 2021 Apr 17;21(1):426. doi: 10.1186/s12885-021-08136-5.
9
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.对于初治的晚期肺鳞状细胞癌患者，采用S-1进行延续性维持治疗。
Invest New Drugs. 2016 Aug;34(4):490-6. doi: 10.1007/s10637-016-0365-4. Epub 2016 Jun 9.
10
The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer.维持性药物治疗非小细胞肺癌的疗效。
Clin Med Insights Oncol. 2012;6:253-62. doi: 10.4137/CMO.S8001. Epub 2012 Jun 11.
引用本文的文献
1
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.肺瘤平膏联合塞来昔布通过环氧化酶-2介导的Lewis肺癌异种移植小鼠模型肺转移炎症微环境发挥抗肿瘤增强作用
J Transl Med. 2015 Nov 23;13:366. doi: 10.1186/s12967-015-0728-1.
本文引用的文献
1
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.ATLAS：一项随机、双盲、安慰剂对照的 IIIB 期临床试验，比较贝伐珠单抗联合或不联合厄洛替尼治疗与贝伐珠单抗单药一线治疗晚期非小细胞肺癌的疗效，化疗后完成。
J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.
2
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.培美曲塞对比多西他赛二线治疗西班牙非小细胞肺癌的成本效果分析：非鳞癌组织学亚组人群结果。
BMC Cancer. 2010 Jan 29;10:26. doi: 10.1186/1471-2407-10-26.
3
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.吉非替尼和多西他赛治疗既往治疗的非小细胞肺癌的分子预后因素：来自随机 III 期 INTEREST 试验的数据。
J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.
4
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.厄洛替尼：在晚期非小细胞肺癌中的药物经济学评价。
Pharmacoeconomics. 2010;28(1):75-92. doi: 10.2165/10482880-000000000-00000.
5
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.美国临床肿瘤学会临床实践指南更新：关于 IV 期非小细胞肺癌的化疗。
J Clin Oncol. 2009 Dec 20;27(36):6251-66. doi: 10.1200/JCO.2009.23.5622. Epub 2009 Nov 16.
6
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.培美曲塞维持治疗联合最佳支持治疗与安慰剂联合最佳支持治疗用于非小细胞肺癌：一项随机、双盲、3期研究
Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18.
7
Screening for epidermal growth factor receptor mutations in lung cancer.肺癌中表皮生长因子受体突变的筛查
N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.
8
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
9
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何：西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
10
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.晚期非小细胞肺癌化疗的疗程：随机试验的系统评价与荟萃分析
J Clin Oncol. 2009 Jul 10;27(20):3277-83. doi: 10.1200/JCO.2008.19.4522. Epub 2009 May 26.
Zotero 插件